Clinical Trial Update: CC-5013 in Treating Patients With Recurrent Glioma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CC-5013 (lenalidomide) in patients with recurrent glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• CC-5013 (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED